Lyell Immunopharma, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $881.2M | $222.6M |
| Jun 2022 | — | $868.0M | $205.7M |
| Sep 2022 | — | $820.0M | $116.3M |
| Dec 2022 | — | $833.3M | $123.6M |
| Mar 2023 | — | $783.8M | $109.4M |
| Jun 2023 | — | $736.9M | $224.4M |
| Sep 2023 | — | $697.6M | $286.2M |
| Dec 2023 | — | $655.0M | $145.6M |
| Mar 2024 | — | $603.2M | $125.7M |
| Jun 2024 | — | $566.5M | $133.4M |
| Sep 2024 | — | $530.7M | $100.3M |
| Dec 2024 | — | $382.8M | $105.6M |
| Mar 2025 | — | $336.5M | $120.3M |
| Jun 2025 | — | $298.9M | $98.8M |
| Sep 2025 | — | $329.1M | $123.6M |
| Dec 2025 | — | $248.2M | $60.2M |
| Mar 2026 | — | $273.7M | $90.8M |
| Jun 2026 | — | $233.8M | $73.0M |